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Background: Aberrant expression of serine threonine tyrosine kinase 1 (STYK1) has been reported in several human
malignancies including colorectal cancer (CRC). However, the prognostic significance of STYK1 expression in CRC
remains unknown.
Methods: STYK1 protein expression in paraffin-embedded CRC specimens was determined immunohistochemically.
The correlation of STYK1 expression with clinicopathologic features was assessed in a cohort containing 353 patients
with primary CRC. Kaplan-Meier and Cox proportional regression analyses were used to evaluate the association between
STYK1 expression and patients’ survival.
Results: STYK1 expression was frequently up-regulated in CRC clinical samples at the protein levels and was significantly
associated with tumor differentiation grade (p = 0.030), lymph node metastasis (p = 0.004), TNM stage (p = 0.007) and
patient death (p < 0.001). Kaplan-Meier analysis indicated that patients with high intratumoral STYK1 expression had a
significantly shorter disease-specific survival (DSS) than those with low expression (p < 0.001). Importantly, high levels of
STYK1 protein predicted poor DSS for both stage II (p < 0.001) and stage III (p = 0.004) patients. Furthermore, multivariate
analyses revealed that STYK1 protein expression was an independent prognostic indicator for both stage II (hazard ratio
[HR], 2.472; p = 0.001) and stage III (HR, 2.001; p = 0.004) patients.
Conclusions: Our results suggest that increased STYK1 protein expression correlates with disease progression and
metastasis and may serve as a predictor of poor survival in CRC.
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Colorectal cancer (CRC) is the third most common can-
cer and the fourth most common cancer cause of death
globally, accounting for more than 1.2 million new cases
and 600,000 deaths every year [1]. Although it was
mainly a disease of the developed countries, the inci-
dence of CRC has continued to increase in several re-
gions including East Asia and Central and East Europe
during the past decades [2,3]. Currently, the prognosis
of CRC patients is highly dependent on clinical stage of
the disease [4], however, huge differences of outcome
exist even among patients of the same stage category [5].* Correspondence: lianghudoc@163.com; guangzyang@163.com; chunfgao@
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markers for the early diagnosis and prognosis prediction
of patients with CRC.
Receptor protein tyrosine kinases (RPTKs) are import-
ant regulators of intracellular signaling pathways mediat-
ing diverse cellular and developmental processes and
their dysregulation are closely related with the develop-
ment of cancer [6,7]. Serine threonine tyrosine kinase 1
(STYK1), also known as novel oncogene with kinase do-
main (NOK), was identified as a new member of the
RPTK-like protein family and found to be expressed in
several normal human tissues [8,9]. It shares about 30%
homology with members of the fibroblast growth factor
receptor/platelet-derived growth factor receptor super-
family, and contains a single putative transmembrane
domain and a conserved intracellular tyrosine kinase do-
main, whereas lacks an extracellular domain for bindings is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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phosphorylation and transmit signals downstream without
ligand binding. Previous investigations have demonstrated
that overexpression of STYK1 could promote cell growth
of prostate cancer cells and leukemia cells [10,11], increase
growth factor-independent proliferation of BaF3 cells and
surface adhesion-independent growth and colony forma-
tion of NIH3T3 and BaF3 cells, and induce tumorigenesis
and metastasis in nude mice [8,12]. These characteristics
indicate that STYK1 has multiple roles in cancer develop-
ment and progression.
Aberrant expression of STYK1 has been previously doc-
umented in human malignancies of the breast, lung, ovary,
blood, and prostate [10,11,13-15], and recently, Orang AV
et al. also reported the significant up-regulation of STYK1
mRNA in CRC tissues [16]. Thus, as an oncogene, STYK1
could be a candidate biomarker for tumor diagnosis and
prognosis prediction. It has been showed that STYK1
mRNA might be a tool to support the diagnosis of breast,
lung, and colorectal carcinomas [13,14,16]. In addition,
the prognostic and therapeutic significance of STYK1
overexpression in human malignant diseases has also been
revealed. Chen P et al. recently demonstrated that in-
creased expression of STYK1 protein correlates with poor
prognosis of patients with non-small cell lung cancer [17].
Nirasawa S et al. provided evidence that STYK1 is a novel
drug resistance factor and could be a potential predictor
of the therapeutic response in acute leukemia [18].
However, the prognostic implication of STYK1 protein
expression in CRC has not been investigated. In the
present study, we evaluated the phenotypic expression of
STYK1 protein immunohistochemically in a large number
of CRC clinical samples and examined the correlation of
STYK1 expression with clinicopathologic features and with
patient survival based on tumor stage. Our data demon-
strated that increased expression of STYK1 was closely re-
lated to disease progression and metastasis and could serve




Formalin-fixed paraffin-embedded tissue specimens
from 353 stages I–III CRC patients who received cura-
tive surgery in 150th Hospital of PLA (Luoyang, China)
from July 2006 to December 2009 were retrieved for im-
munohistochemistry. The study cohort consisted of CRC
patients with typical adenocarcinoma histology as con-
firmed by pathological analysis. Detailed clinicopathologic
characteristics of the patients were listed in Table 1. The
follow-up period was defined as the interval from the date
of surgery to the date of death or last follow-up. The final
date of follow-up was 30 September 2014, and the median
follow-up time of the cohort was 66 months (range, 2–98months). Disease-specific survival (DSS) was defined as the
interval from the date of surgery to the date that patient
died of CRC. Patients alive at the end of follow-up were
censored. Patients were excluded from the study cohorts
with the following exclusion criteria: previously received
any anticancer therapy; impaired heart, lung, liver, or
kidney function; previous malignant disease. TNM staging
was classified according to the American Joint Committee
on Cancer staging manual (seventh edition). Written in-
formed consent was obtained from each patient and this
study was approved by the Ethical Committee of 150th
Hospital of PLA.
Tissue microarray and immunohistochemistry
Tissue microarrays (TMAs) containing the specimens
from 150th Hospital of PLA were constructed (Shanghai
Biochip Company Ltd, Shanghai, China). Immunohisto-
chemistry of paraffin-embedded tissue sections was per-
formed as described previously [19]. Briefly, sections
were deparaffinized and rehydrated. The endogenous
peroxidase activity was blocked with 3% H2O2 for
10 minutes. Antigens were retrieved with citrate buffer
(10 mM, pH 6.0) for 15 minutes at 100°C in a microwave
oven. After blocking, the sections were incubated with a
primary anti-STYK1 antibody (Abcam, ab97451) with 1:200
dilution at 4°C overnight in a moist chamber followed by
incubated with an anti-rabbit peroxidase-conjugated sec-
ondary antibody (Santa Cruz) at room temperature for
30 minutes. Finally, the visualization signal was developed
with diaminobenzidine (Dako) and the slides were counter-
stained with hematoxylin.
Stained sections were evaluated in a blinded manner
without prior knowledge of the clinical data using the
German immunoreactive score (IRS), as described previ-
ously [20,21]. Briefly, staining intensity was graded as “0”
(negative), “1” (weak), “2” (moderate) and “3” (strong);
staining extent was graded as “0” (<5%), “1” (5-25%), “2”
(25-50%), “3” (50-75%) and “4” (>75%). Values of the
staining intensity and the staining extent were multiplied
as a final IRS of STYK1 expression, which ranged from
0 to 12. The median value of the IRS was chosen as the
cut-off for high and low STYK1 expression levels based
on a measure of heterogeneity according to the log-rank
test with respect to DSS, as described previously [22].
An IRS of ≥ 6 was used to define tumors with high STYK1
expression and an IRS of < 6 was used to indicate tumors
with low STYK1 expression. If there was a discrepancy in
individual evaluations, then the cases were reevaluated to-
gether with other pathologists to reach a consensus.
Statistical analysis
Pearson chi-square test or Fisher exact test was used to
analyze the relationship between STYK1 expression and
clinical features. Kaplan-Meier analysis with log-rank test
Table 1 Association Between STYK1 Expression and Clinicopathologic Characteristics of CRC Patients in the Study Cohort
Characteristics No. of STYK1 expression
patients (%) Low (%) High (%) P value a
(n = 353) (n = 213) (n = 140)
Age (years) 0.783
<60 93 (26.3) 55 (25.8) 38 (27.1)
≥60 260 (73.7) 158 (74.2) 102 (72.9)
Sex 0.403
Female 166 (47.0) 104 (48.8) 62 (44.3)
Male 187 (53.0) 109 (51.2) 78 (55.7)
Tumor location 0.908
Rectum 155 (43.9) 93 (43.7) 62 (44.3)
Colon 198 (56.1) 120 (56.3) 78 (55.7)
Differentiation grade 0.030
Well 33 (9.3) 27 (12.7) 6 (4.3)
Moderate 256 (72.5) 149 (70.0) 107 (76.4)
Poor 64 (18.2) 37 (17.3) 27 (19.3)
Tumor size (cm) 0.950
<5 152 (43.1) 92 (43.2) 60 (42.9)
≥5 201 (56.9) 121 (56.8) 80 (57.1)
Local invasion 0.055
T1-T2 48 (13.6) 35 (16.4) 13 (9.3)
T3-T4 305 (86.4) 178 (83.6) 127 (90.7)
Lymph node metastasis 0.004
N0 209 (59.2) 140 (65.7) 69 (49.3)
N1 108 (30.6) 58 (27.2) 50 (35.7)
N2 36 (10.2) 15 (7.1) 21 (15.0)
TNM stage 0.007
I 43 (12.2) 31 (14.6) 12 (8.6)
II 166 (47.0) 109 (51.2) 57 (40.7)
III 144 (40.8) 73 (34.2) 71 (50.7)
Death <0.001
No 211 (59.8) 150 (70.4) 61 (43.6)
Yes 142 (40.2) 63 (29.6) 79 (56.4)
a Pearson chi-square test or Fisher exact test was used for comparison between subgroups. Bold type indicates statistical significance.
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The effect of each variable on survival was determined by
the Cox multivariate regression analysis. All statistical ana-
lyses were carried out using SPSS PASW Statistics 18.0
software (SPSS, Inc., Chicago, IL), and p value < 0.05 were
considered to be statistically significant.
Results
Expression of STYK1 protein in primary CRC tissues
To determine the phenotypic expression of STYK1 pro-
tein in CRC clinical samples, immunohistochemical ana-
lysis was performed using a tissue microarray containing
353 pairs of CRC specimens. Each pair consisted ofcancerous and adjacent normal colorectal mucosa speci-
mens derived from the same patient. As representatively
shown in Figure 1A, positive staining of STYK1 was ob-
served mainly in the cytoplasm of cancer cells and the
immunostaining intensity of STYK1 protein was graded
to four levels including negative, weak, moderate and
strong. In all, 4.6% (16/353) of the cancerous specimens
showed strong staining, 50.1% (177/353) of the cases
showed moderate staining, 33.1% (117/353) of the cases
showed weak staining and only 12.2% (43/353) of the
cases showed negative staining of STYK1 protein. In
striking contrast, 51.6% (182/353) of the corresponding
adjacent normal tissues showed negative staining, 40.2%
Figure 1 Expression of STYK1 protein in primary CRC tissues. (A) Immunohistochemical characteristics of STYK1 in cancerous and adjacent
normal mucosa specimens. Representative patterns of STYK1 expression were shown. (Magnification, left panel, ×40; right panel, ×200) (B)
Percentage of cases with different staining intensity of STYK1 in the tumor or adjacent normal tissues in the study cohort. (p < 0.001).
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353) of the cases showed moderate staining and none of
the cases showed strong staining of STYK1 (Figure 1B,
p < 0.001). Thus, STYK1 protein expression was fre-
quently upregulated in CRC.Relationship between STYK1 protein expression and
clinical features
The clinicopathologic characteristics of the 353 CRC
patients were summarized in Table 1. To evaluate the
association between STYK1 protein levels and clinico-
pathologic characteristics, the patients were classified
into high and low intratumoral STYK1 expression sub-
groups with the median IRS value as the cut-off. As the
results shown in Table 1, high expression of STYK1
protein was significantly associated with poor tumor
differentiation (p = 0.030), increased lymph node me-
tastasis (p = 0.004), advanced TNM stage of the disease
(p = 0.007) and increased death (p < 0.001). While,
there were no significant associations between STYK1
expression and patient age (p = 0.783), sex (p = 0.403),
tumor location (p = 0.908), tumor size (p = 0.950) or
local invasion (p = 0.055).Prognostic values of STYK1 expression for patients with
CRC
To investigate the relationship between STYK1 expression
and the clinical outcome of CRC patients, Kaplan-Meier
analysis and the log-rank test were used to assess the ef-
fects of STYK1 on patient survival. The results showed
that patients with high intratumoral STYK1 expression
had a significantly shorter DSS than those with low
STYK1 expression (Figure 2A, p < 0.001). For patients
with low STYK1 expression, the 1-year, 3-year and 5-year
DSS were 95.3%, 80.3% and 73.7%, while patients with
high STYK1 expression had 1-year, 3-year and 5-year DSS
of 85.7%, 62.1% and 46.4%, respectively. In our cohort, pa-
tients who had advanced TNM stage (stage III) tumors
had a significantly worse prognosis compared with those
who had early stage (stage I and II) tumors (Additional file
1, p < 0.001).
To test the prognostic value of STYK1 in patients with
the same stage category, we stratified patients based on
stage and further performed survival analysis according
to the expression of STYK1 protein. Notably, high ex-
pression of STYK1 protein significantly predicted poor
DSS not only in stage II patients (Figure 2B, p < 0.001)
but also in stage III patients (Figure 2C, p = 0.004).
Figure 2 Kaplan-Meier survival analysis for CRC patients.
Kaplan-Meier curves for disease-specific survival of all CRC patients in
the study cohort (A), stage II patients (B) and stage III patients (C)
according to STYK1 expression status. Patients were divided into high
and low STYK1 expression subgroups with the median IRS value as the
cut-off. The p-value was determined using the log-rank test.
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independent prognostic indicator in CRC, the effect of
each variable on survival was determined by the Cox
regression analysis. Univariate analyses revealed that
differentiation grade (HR = 1.495, 95%CI = 1.004-2.227,
p = 0.048), TNM stage (HR = 2.262, 95%CI = 1.625-
3.150, p < 0.001) and STYK1 expression (HR = 2.340,
95%CI = 1.679-3.262, p < 0.001) showed significantly
higher hazard ratios for a poor prognosis. The parame-
ters that significantly correlated with survival in the
univariate analysis were further assessed by multivariate
analysis. The results of the multivariate analysis re-
vealed that, besides TNM stage (HR = 2.033, 95%CI =
1.455-2.840, p < 0.001), STYK1 expression was an inde-
pendent prognostic indicator (HR = 2.116, 95%CI =
1.513-2.960, p < 0.001) (Table 2).
In addition, the independent prognostic significance of
STYK1 protein expression on CRC-specific survival
based on TNM stage was further evaluated with a Cox
regression model. The results showed that increased ex-
pression of STYK1 protein was an independent indicator
of a poor prognosis for both stage II patients (HR =
2.472, 95%CI = 1.445-4.229, p = 0.001) and stage III pa-
tients (HR = 2.001, 95%CI = 1.251-3.200, p = 0.004). For
stage III patients, differentiation grade also was signifi-
cantly associated with patient survival (HR = 1.680; 95%
CI = 1.033-2.733, p = 0.037) (Table 3).
Discussion
RPTKs have been implicated in the regulation of a var-
iety of cellular processes including cell proliferation, sur-
vival, differentiation, migration and apoptosis through
various signaling pathways [6,7]. According to previous
reports, humans express at least 58 RPTKs [23]. Nor-
mally, the activity of RPTKs is highly controlled. While,
perturbation of RPTKs by aberrant expression or muta-
tion could promote cellular transformation and tumori-
genesis [24]. Numerous studies have implicated RPTKs
as oncogenes, and several RPTKs such as EGFR, VEGFR,
HER2 have been selected as targets in cancer therapy
[25]. Phylogenetic tree analysis indicated that STYK1 be-
longs to a distant member of FGFR/PDGFR family [8].
Functional studies demonstrated that STYK1 has the
ability to promote cell proliferation, induce transform-
ation and tumorigenesis and facilitate tumor cell inva-
sion and metastatic progression [8,10-12]. Mechanistic
investigations revealed that STYK1 could concomitantly
activate both the MAPK and PI3K pathways, indicating
that it may be standing out as a distinct member of the
RPTK family [8]. In addition, a recent study showed that
STYK1 interacts and forms complexes with both Akt
and GSK-3beta and enhances phosphorylation of GSK-
3beta at its Ser9 residue via Akt phosphorylation at
Thr308 [26]. Given the importance of the MAPK, PI3K,
Table 2 Univariate and Multivariate Analyses of STYK1 Expression and Disease-Specific Survival of Patients in the
Study Cohort
Variables Categories Univariate analysis Multivariate analysisb
HR 95% CI P valuec HR 95% CI P valuec
Age ( years) ≥60 / <60 1.182 0.801-1.745 0.399
Sex Male / female 1.223 0.878-1.704 0.234
Tumor location Colon / rectum 1.042 0.745-1.456 0.811
Tumor size (cm) ≥5 / <5 1.266 0.904-1.773 0.170
Differentiation grade Poor / well + moderate 1.495 1.004-2.227 0.048
TNM stage III / I+ II 2.262 1.625-3.150 <0.001 2.033 1.455-2.840 <0.001
STYK1 expressiona High / low 2.340 1.679-3.262 <0.001 2.116 1.513-2.960 <0.001
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval.
a For STYK1, the median value of the IRS was used as the cut-off point for definition of subgroups (low expression and high expression groups).
b Multivariate models were adjusted for age, sex, tumor location, tumor size, differentiation grade, and TNM stage.
c Bold type indicates statistical significance.
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man cancers, these molecular findings may, in part, ac-
count for the oncogenic property of STYK1 protein.
Due to the potential significance of STYK1 in cancer
biology, its clinical relevance in human malignancies has
aroused increasing attention. The diagnostic implication
of STYK1 mRNA has been demonstrated in cancers of
breast, lung and colorectum [13,14,16]. In addition, the
prognostic value of STYK1 protein expression in non-
small cell lung cancer has also been revealed [17]. More-
over, it has been clarified recently that measurement of
STYK1 mRNA expression could be a potential marker
for predicting the therapeutic outcome of various types
of acute leukemia [18]. To date, only one study investi-
gated the expression of STYK1 in CRC. Using 36 pairs
of CRC tissues, Orang AV et al. performed qRT-PCR
analysis and found that STYK1 mRNA expression was
significantly elevated in cancerous tissues when com-
pared to matched adjacent non-cancerous counterparts
[16]. Nevertheless, the prognostic significance of STYK1
expression has not been assessed in CRC.
To the best of our knowledge, the current study is the
first to report the prognostic value of STYK1 proteinTable 3 Multivariate Analyses of STYK1 Expression and Disea
Study Cohort
Variables Categories Stage II Patients
HR 95%
Age ( years) ≥60 / <60 1.421 0.70
Sex Male / female 0.956 0.55
Tumor location Colon / rectum 0.819 0.47
Tumor size (cm) ≥5 / <5 1.324 0.76
Differentiation grade Poor / well + moderate 0.854 0.32
STYK1 expressiona High / low 2.472 1.44
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval.
a For STYK1, the median value of the IRS was used as the cut-off point for definition
b Bold type indicates statistical significance.expression in primary CRC tissues. Immunohistochemi-
cal analysis of 353 paired CRC specimens revealed that
STYK1 protein was mainly localized in the cytoplasm
and 87.8% (310/353) of the cancerous tissues tested were
STYK1 positive staining, whereas only 48.4% (171/353)
of the adjacent normal mucosa tissues showed weak-
moderate STYK1 immunoreactivity. These results were
in agreement with the previous findings of Orang AV et
al. at the mRNA level [16] and definitely confirmed the
significant up-regulation of STYK1 protein in CRC.
Similar to what we observed in the present study, earlier
investigations reported that STYK1 was overexpressed in
several solid and hematological tumors [10,11,13-15,17].
However, the underlying mechanism of STYK1 overex-
pression in CRC is currently unknown and requires further
investigation.
According to our results, increased expression of
STYK1 protein was significantly correlated with poor
tumor differentiation, increased lymph node metastasis
and advanced TNM stage of the disease, indicating that
STYK1 may be involved in the progression of CRC.
Likewise, Chen P et al. also demonstrated a significant
correlation of STYK1 protein expression with the gradese-Specific Survival for Stage II and III Patients in the
Stage III Patients
CI P valueb HR 95% CI P valueb
5-2.865 0.326 1.475 0.883-2.463 0.138
6-1.645 0.872 1.132 0.718-1.784 0.594
2-1.420 0.478 1.158 0.729-1.840 0.534
8-2.284 0.312 1.389 0.863-2.235 0.176
5-2.245 0.749 1.680 1.033-2.733 0.037
5-4.229 0.001 2.001 1.251-3.200 0.004
of subgroups (low expression and high expression groups).
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tastasis in non-small cell lung cancer [17]. However,
Orang AV et al. reported that the high expression of
STYK1 mRNA in CRC was only correlated with the in-
creased tumor size in their cohort [16]. Similar to Orang
AV’s findings, an earlier study conducted by Amachika T
et al. showed that there were no obvious correlations be-
tween STYK1 mRNA expression and clinicopathologic
features of patients with lung cancer [14]. Of note,
Orang AV et al. and Amachika T et al. studied the
mRNA expression levels of STYK1 in fresh-frozen sam-
ples, while Chen P et al. and we investigated STYK1
protein levels in formalin-fixed paraffin-embedded tissue
specimens. Therefore, these discrepancies may be due to
the different type of studies and samples.
Interestingly, in the present study, we observed a sig-
nificant association between increased STYK1 protein
expression and poor patient survival in both univariate
and multivariate survival analyses. Our findings are also
similar to the results from Chen P et al. [17], in that
they demonstrated that increased expression of STYK1
protein was significantly associated with shortened sur-
vival in patients with lung cancer. In addition, our re-
sults demonstrated that TNM stage also is an important
prognostic factor in CRC, which is consistent with the
well established adverse prognostic effect of tumor stage
[27] and confirm that our cohort was representative and
that the survival analyses were valid. More importantly,
our stage-based survival analyses confirmed that in-
creased expression of STYK1 protein not only signifi-
cantly predicted poor DSS but also was an independent
predictor of poor prognosis in stage II as well as in stage
III patients. These findings should be of particular inter-
est especially for stage II patients. It is well known that
CRC prognosis is highly stage dependent and that TNM
staging is still a solid basis for therapeutic decision-
making, however, dilemmas still exist with regard to the
selection of stage II patients for appropriate treatment.
In general, stage II CRC patients have a more favorable
outcome than stage III patients [1]. Nevertheless, a sub-
group of stage II patients have an increased risk of early
recurrence and death. Therefore, identification of this
high-risk subgroup of stage II CRC patients by markers
is of great clinical need for prognosis prediction. Thus,
our current results suggest that STYK1 protein expres-
sion status could be a promising biomarker to stratify
stage II patients into distinct risk subgroup and guide in-
dividualized therapy choices.
The potential mechanism for the prognostic importance
of STYK1 oncogene overexpression in CRC is unknown
and needs to be further investigated. Nevertheless, the
reported abilities of STYK1 to increase cell proliferation,
induce malignant transformation, and promote tumorige-
nesis and metastasis may, at least partly, explain the reasonwhy increased STYK1 protein expression correlates with
disease progression and poor prognosis of patients with
CRC.
There were several shortcomings in this work. Al-
though our results demonstrated prognostic values for
STYK1 protein expression in a cohort of CRC patients,
they did not elucidate the role of STYK1 expression in
CRC development. In addition, due to the limitation of
follow-up period, the median survival time of patients
with low STYK1 expression had not been reached, thus,
results from the present work could not accurately re-
flect the survival of patients in this subgroup. Moreover,
disease relapse monitoring was incomplete for 84 of the
353 patients, resulting in the loss of disease-free survival
data, which is also important for a biomarker validation.
Further studies are needed to confirm our findings be-
fore clinical translation and to provide a better under-
standing of the function and mechanism of STYK1
expression in the development and progression of CRC.
Conclusions
We report here, for the first time, that upregulated ex-
pression of STYK1 protein was significantly correlated
with disease progression and poor postoperative progno-
sis of CRC patients. Thus, as a novel RPTK, STYK1
might represent a promising prognostic biomarker and
potential therapeutic target for patients with CRC.
Additional file
Additional file 1: Kaplan-Meier curves for disease-specific survival
of all CRC patients according to TNM stage of the disease. The p-value
was determined using the log-rank test.
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